A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discovery
Roncador M. et al, (2025), Blood Journal
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Borate U. et al, (2025), Blood
Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
Bernard E. et al, (2024), Blood, 144, 1617 - 1632
Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.
Pellagatti A. and Boultwood J., (2024), Adv Biol Regul
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M. et al, (2024), Blood, 144, 1221 - 1229
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.
Casalin I. et al, (2024), Adv Biol Regul
Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies
Tatwavedi D. et al, (2023), Advances in Biological Regulation, 100993 - 100993
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S. et al, (2023), Clin Epigenetics, 15
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.
Robbe P. et al, (2022), Nat Genet, 54, 1675 - 1689
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
Stahl M. et al, (2022), Blood Adv
Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A. and Boultwood J., (2022), Adv Biol Regul
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS. et al, (2022), Elife, 11
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V. et al, (2022), EBioMedicine, 80